Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Endocyte Inc.

Apr 2009
Endocyte Inc. of West Lafayette, Ind., has initiated a randomized Phase II clinical study of its EC145 drug in women with platinum-resistant ovarian cancer. In addition to the drug, patients will be treated with the company’s EC20 molecular imaging agent, which enables clinicians to identify tumors that overexpress folate receptors.

BiophotonicsEndocyte Inc.molecular imagingNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.